News | August 16, 2021
Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
EPS for the period at Rs. (7.57)
EPS for the period at Rs. (7.57)
The group has a total of 320 ANDA approvals
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Studies include Alpha, Beta, Gamma, Delta, Epsilon and Iota and it maintains antibodies for six months after the second dose
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Subscribe To Our Newsletter & Stay Updated
